Novel inhalation therapies for rare lung diseases
Giving lung patients with unmet medical needs an option.
Introducing Serendex
Serendex Pharmaceuticals A/S is a Denmark based pharmaceutical development company founded in 2008. We are advancing a pipeline of novel inhalation therapies for the treatment of patients with severe pulmonary conditions.
We focus on two biologic compounds and three orphan drug indications.
GM-CSF for PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome)
Factor VIIa for DAH (diffuse alveolar hemorrhage)
All of these conditions have an acute or chronic nature but no satisfactory method of treatment. Hence, there is a high unmet medical need among patients with these conditions worldwide.
Serendex develops novel therapies for critical lung diseases. We are entirely focused on inhaled drug delivery because topical (local) therapy is usually much safer than systemic therapy.
As a specialty biopharmaceutical drug development company we identify novel pulmonary uses for known drugs. We have filed for 10 new use patents for 8 already approved and marketed drugs for high-mortality patients with difficult-to-treat lung disease indications.
"Drug-Transformation" is the term we use to describe our drug development process – from idea, via IP rights to clinical development.
Novel inhalation therapies for severe lung diseases
Serendex focuses on developing new inhalation treatments for patients who suffer from rare and serious respiratory diseases. We are advancing a pipeline based on two biological compounds: GM-CSF and Factor VIIa.
Both have been widely used as active pharmaceutical ingredients in medicinal products licensed for systemic use before but never in medicinal products licensed for inhalation.
Treating lung diseases by inhalation makes sense. Based on the clinical documentation that already exists, the prospects of using GM-CSF and FVIIa for inhalation are promising. This is the rationale behind our business strategy.
Our use of GM-CSF and FVIIa is based on three basic elements:
New unique formulations
New administration routes
New indications
We focus on orphan indications such as PAP (pulmonary alveolar proteinosis), ARDS (acute respiratory distress syndrome) and DAH (diffuse alveolar hemorrhage), where there is a worldwide unmet medical need.
In 2018 we expect a marketing approval for inhalation of GM-CSF for PAP and we look forward to be able to contribute to the health of patients suffering from serious lung diseases going forward.
Investor Relations
Serendex aims to disclose clear, precise, timely, and balanced information to the capital market. Hence, on these pages you will find the necessary material for you to form a qualified opinion of the company and its prospects, e.g financial reports, financial calendar and stock exchange notices.
Serendex in short
Serendex Pharmaceuticals A/S (“SENDEX” Oslo Axess) is a Danish pharmaceutical company, which engages in the development of drugs to treat serious respiratory conditions. Founded in 2008, the company has developed a portfolio of compounds, which includes granulocyte macrophage colony stimulating factor (GM-CSF) and Factor VIIa. These active pharmaceutical ingredients (APIs) can be used for the treatment of diseases such as pulmonary alveolar proteinosis (PAP), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), cystic fibrosis (CF), and diffuse alveolar hemorrhage (DAH). Marketing approval of inhaled GM-CSF for the treatment of PAP is expected in 2018 i Europe.
If you have any questions please contact Nadia Vega Vasiljev, Head of Communications and Investor Relations.